Patents by Inventor Shulong Wang
Shulong Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10745383Abstract: Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.Type: GrantFiled: July 29, 2016Date of Patent: August 18, 2020Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.Inventors: Na Zhao, Shulong Wang, Xijie Liu, Yuandong Hu, Hui Zhang, Hong Luo, Yong Peng, Yongxin Han, Xiquan Zhang, Hongjiang Xu
-
Patent number: 10654826Abstract: Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.Type: GrantFiled: July 29, 2016Date of Patent: May 19, 2020Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.Inventors: Na Zhao, Shulong Wang, Xijie Liu, Yuandong Hu, Hui Zhang, Hong Luo, Yong Peng, Yongxin Han, Xiquan Zhang, Hongjiang Xu
-
Patent number: 10570141Abstract: The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.Type: GrantFiled: March 27, 2017Date of Patent: February 25, 2020Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.Inventors: Shulong Wang, Kuncheng Chen, Xijie Liu, Yuandong Hu, Bo Liu, Yong Peng, Hong Luo, Yongxin Han, Shanchun Wang, Mei Liu, Hongjiang Xu
-
Publication number: 20190300533Abstract: The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect.Type: ApplicationFiled: March 27, 2017Publication date: October 3, 2019Inventors: Shulong Wang, Kuncheng Chen, Xijie Liu, Yuandong Hu, Bo Liu, Yong Peng, Hong Luo, Yongxin Han, Shanchun Wang, Mei Liu, Hongjiang Xu
-
Publication number: 20190062308Abstract: Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers.Type: ApplicationFiled: July 29, 2016Publication date: February 28, 2019Inventors: Na ZHAO, Shulong WANG, Xijie LIU, Yuandong HU, Hui ZANG, Hong LUO, Yong PENG, Yongxin HAN, Xiquan ZHANG, Hongjiang XU
-
Patent number: 10155722Abstract: The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers.Type: GrantFiled: July 29, 2016Date of Patent: December 18, 2018Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang Runzhong Pharmaceutical Co., Ltd., Centaurus Biopharma Co., Ltd.Inventors: Shulong Wang, Na Zhao, Xijie Liu, Yuandong Hu, Hui Zhang, Hong Luo, Yong Peng, Dengming Xiao, Yongxin Han, Xiquan Zhang, Xin Tian
-
Publication number: 20180222853Abstract: The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers.Type: ApplicationFiled: July 29, 2016Publication date: August 9, 2018Inventors: Shulong WANG, Na ZHAO, Xijie LIU, Yuandong HU, Hui ZHANG, Hong LUO, Yong PENG, Dengming XIAO, Yongxin HAN, Xiquan ZHANG, Xin TIAN
-
Patent number: 9499530Abstract: A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.Type: GrantFiled: July 21, 2012Date of Patent: November 22, 2016Assignees: HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCH, HANGZHOU MINSHENG PHARMACEUTICAL CO. LTDInventors: Shulong Wang, Jian Cai, Qiufu Ge, Dianwu Guo, Lan Yang, Binnan Huang, Zhenhua Liu, Zhonghua Peng, Ximing Shen, Feiyu Feng
-
Patent number: 9428508Abstract: The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.Type: GrantFiled: January 7, 2012Date of Patent: August 30, 2016Assignee: Centaurus BioPharma Co., Ltd.Inventors: Dengming Xiao, Liang Cheng, Xijie Liu, Yuandong Hu, Xinhe Xu, Zhihua Liu, Lipeng Zhang, Wei Wu, Shulong Wang, Yu Shen, Gen Li, Yin Wang, Sheng Zhao, Chonglong Li, Jia Tang, Honghao Yu
-
Patent number: 9127655Abstract: The disclosure relates to liquid nitrogen pump equipment load testing and experimenting apparatus, and testing and experimenting method thereof, used for oil-gas fields or coalbed methane nitrogen foam fracturing equipment testing. A hydraulic damping apparatus unit and a pressure regulation unit are provided; the hydro-mechanical damping apparatus unit comprises a water tank, a pump unit apparatus, and a pipe manifold system connected in sequence.Type: GrantFiled: September 28, 2011Date of Patent: September 8, 2015Assignees: China National Petroleum Corporation, CNPC Bohai Equipment Manufacturing Co., Ltd.Inventors: Shulong Wang, Xianying Tan, Xiaolin Wang, Hongguang Zhang, Yongqing Shi, Fang Gu
-
Publication number: 20150080392Abstract: A class of quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof with novel structures is provided; meanwhile, a pharmaceutical composition comprising a pharmaceutically effective amount of said quinazoline derivatives or pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients or additives is also provided. By modifying and transforming the quinazoline and screening of the transformed compounds on the activity of tyrosine kinase inhibition, most of the compounds have been found to possess inhibitory activity against one or several of EGFR, VEGFR-2, c-erbB-2, c-erbB-4, c-met, tie-2, PDGFR, c-src, lck, Zap70 and fyn kinases. The present invention has the advantages of reasonable design, broad source of and easy access to the raw materials, simple and easy operation of the preparation methods, mild reaction conditions, high yield of the products and being beneficial for industrial-scale production.Type: ApplicationFiled: July 21, 2012Publication date: March 19, 2015Applicants: HANGZHOU MINSHENG PHARMACEUTICAL CO. LTD, HANGZHOU MINSHENG INSTITUTES FOR PHARMA RESEARCHInventors: Shulong Wang, Jian Cai, Qiufu Ge, Dianwu Guo, Lan Yang, Binnan Huang, Zhenhua Liu, Zhonghua Peng, Ximing Shen, Feiyu Feng
-
Publication number: 20130281438Abstract: The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.Type: ApplicationFiled: January 7, 2012Publication date: October 24, 2013Applicant: CENTAURUS BIOPHARMA CO., LTD.Inventors: Dengming Xiao, Liang Cheng, Xijie Liu, Yuandong Hu, Xinhe Xu, Zhihua Liu, Lipeng Zhang, Wei Wu, Shulong Wang, Yu Shen, Gen Li, Yin Wang, Sheng Zhao, Chonglong Li, Jia Tang, Honghao Yu
-
Publication number: 20130195690Abstract: The disclosure relates to liquid nitrogen pump equipment load testing and experimenting apparatus, and testing and experimenting method thereof, used for oil-gas fields or coalbed methane nitrogen foam fracturing equipment testing. A hydraulic damping apparatus unit and a pressure regulation unit are provided; the hydro-mechanical damping apparatus unit comprises a water tank, a pump unit apparatus, and a pipe manifold system connected in sequence.Type: ApplicationFiled: September 28, 2011Publication date: August 1, 2013Applicants: CNPC Bohai Equipment Manufacturing Co., Ltd., China National Petroleum CorporationInventors: Shulong Wang, Xianying Tan, Xiaolin Wang, Hongguang Zhang, Yongqing Shi, Fang Gu
-
Patent number: 7700584Abstract: The present invention provides curcumol derivatives of the following formula (I) or pharmaceutical acceptable salts thereof: wherein, Y is selected from the group consisting of ?CHR2, —CH2R2, ?O, ?—OH or —OR1;R1 is selected from H, R, RCO or HO3S; and R is selected from the group consisting of H; saturated or unsaturated linear C1-10 hydrocarbon group and the like; R2 is selected from the group consisting of F; Cl; Br; I; H; —OH; —OR; —HSO3 and the like; with the proviso that both R1 and R2 are not H. The present invention also provides anti-tumor or antiviral pharmaceutical compositions comprising said derivatives or pharmaceutical acceptable salts thereof. The present invention further provides the use of said derivatives or pharmaceutical acceptable salts thereof in the preparation of a medicament for prophylaxis and/or treatment tumor or an antiviral medicament.Type: GrantFiled: May 26, 2005Date of Patent: April 20, 2010Assignee: Hangzhou Minsheng Pharmaceuticals Co., Ltd.Inventors: Shulong Wang, Dianwu Guo, Zhaoke Meng
-
Patent number: 7435838Abstract: The present invention relates to the diol intermediate of citalopram useful for treatment of depression, which is the crystal of free base of 3-hydroxylmethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)]butylbenzonitrile and the method of crystallization thereof. The present invention has disclosed the method to prepare pure citalopram and its purified salts through crystallization of the described base; the optical resolution method of citalopram diol intermediate, the method to prepare S-citalopram and its purified salts by crystals mentioned above. The present invention has also disclosed the method to prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as pharmaceutical formulation thereof obtained. Using methods of the present invention, the quality and yield of the product can be significantly improved, and the production cost of the medicinal material can be reduced.Type: GrantFiled: December 6, 2004Date of Patent: October 14, 2008Assignee: Hangzhou Minsheng Pharmaceutical Co. Ltd.Inventors: Runan Mei, Dianwu Guo, Shulong Wang
-
Publication number: 20070191360Abstract: The present invention provides curcumol derivatives of the following formula (I) or pharmaceutical acceptable salts thereof: wherein, Y is selected from the group consisting of ?CHR2, —CH2R2, ?O, ?—OH or —OR1;R1 is selected from H, R, RCO or HO3S; and R is selected from the group consisting of H; saturated or unsaturated linear C1-10 hydrocarbon group and the like; R2 is selected from the group consisting of F; Cl; Br; I; H; —OH; —OR; —HSO3 and the like; with the proviso that both R1 and R2 are not H. The present invention also provides anti-tumor or antiviral pharmaceutical compositions comprising said derivatives or pharmaceutical acceptable salts thereof. The present invention further provides the use of said derivatives or pharmeceutical acceptable salts thereof in the preparation of a medicament for prophylaxis and/or treatment tumor or an antiviral medicament.Type: ApplicationFiled: May 26, 2005Publication date: August 16, 2007Applicant: HANGZHOU MINSHENG PHARMACEUTICALS CO., LTD.Inventors: Shulong Wang, Dianwu Guo, Zhaoke Meng
-
Publication number: 20070117992Abstract: The present invention relates to the diol intermediate of citalopram useful for treatment of depression, that is to say, the crystal of free alkali of 3-hydroxylmethyl-4-[1-(4-fluorophenyl)-1-hydroxyl-4-(dimethylamino)] butylbenzonitrile and the method of crystallization thereof. The present invention has disclosed the method to prepare pure citalopram and its purified salts through crystallization of the described alkali;the optical resolution method of citalopram diol intermediate, the method to prepare S-citalopram and its purified salts by crystals mentioned above. The present invention has also disclosed the method to prepare citalopram and its purified salts, S-citalopram and its purified salts, as well as pharmaceutical formulation thereof obtained. Using methods of the present invention, the quality and yield of the product can be signally improved, and the production cost of the medicinal material can be decreased.Type: ApplicationFiled: December 6, 2004Publication date: May 24, 2007Inventors: Runan Mei, Dianwu Guo, Shulong Wang